organization · Reporting owner

Alexandria Venture Investments, LLC

Disclosed activity across 21 companies

Tapewire entity: 90213
SEC CIK: 0001722024

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Applied Therapeutics, Inc.APLT · Entity 67708	10% owner	June 04, 2024	June 06, 2024
TRex Bio, Inc.TRXB · Entity 184308	10% owner	October 08, 2026	October 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Applied Therapeutics, Inc.

Report date June 04, 2024 · Filed June 06, 2024

Jointly reported with ALEXANDRIA REAL ESTATE EQUITIES, INC., Alexandria Equities No. 7, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy subsidiary	6,005,077	Reported balance After 2024-06-04 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2024-06-04 · Sale · Disposed 150,000 · Balance 6,005,077 F1: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.12 to $4.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
Common StockSEC Table I · non-derivative	IndirectBy subsidiary	5,855,077	Reported balance After 2024-06-05 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2024-06-05 · Sale · Disposed 150,000 · Balance 5,855,077 F3: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.10 to $4.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
Common StockSEC Table I · non-derivative	IndirectBy subsidiary	203,977	Reported balance Holding disclosure · report date 2024-06-04 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 203,977 F4: These securities are held directly by AE7, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.12 to $4.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.

F3: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.10 to $4.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: These securities are held directly by AE7, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.

TRex Bio, Inc.

Report date October 08, 2026 · Filed October 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A-3 Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-10-08 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The preferred stock is convertible into the Issuer's common stock at a ratio of 3.8649 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-10-08 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: The preferred stock is convertible into the Issuer's common stock at a ratio of 3.8649 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.

Filing footnotes · ownership attribution and instrument terms

F1: The preferred stock is convertible into the Issuer's common stock at a ratio of 3.8649 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.

Past disclosures · reporting ended (19)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARS Pharmaceuticals, Inc.

Report date December 08, 2020 · Filed December 08, 2020

Section 16 reporting ended · disclosed 2020-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	699,412	Reported balance After 2020-12-08 transaction · row 1 1 source row Row 1 · 2020-12-08 · Conversion · Acquired 699,412 · Balance 699,412 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.
Series A redeemable convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-12-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-08 · Conversion · Disposed 1,428,570 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B redeemable convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-12-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-08 · Conversion · Disposed 1,168,347 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Avidity Biosciences, Inc.

Report date June 16, 2020 · Filed June 16, 2020

Section 16 reporting ended · disclosed 2020-06-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	502,365	Reported balance After 2020-06-16 transaction · row 1 1 source row Row 1 · 2020-06-16 · Conversion · Acquired 502,365 · Balance 502,365 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date.
Series A convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-06-16 · Conversion · Disposed 395,000 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-16 · Conversion · Disposed 530,616 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series C convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-06-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-06-16 · Conversion · Disposed 134,126 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

CONSTELLATION PHARMACEUTICALS INC

Report date July 23, 2018 · Filed July 23, 2018

Section 16 reporting ended · disclosed 2018-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	216,304	Ending reported balance After 2018-07-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-07-23 · Conversion · Acquired 149,637 · Balance 149,637 F1: Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Row 2 · 2018-07-23 · Purchase · Acquired 66,667 · Balance 216,304
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-23 · Conversion · Disposed 208,333 · Balance 0 F1: Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: Not applicable.
Series D convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-23 · Conversion · Disposed 10,454 · Balance 0 F1: Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: Not applicable.
Series E convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-23 · Conversion · Disposed 111,111 · Balance 0 F2: Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: Not applicable.
Series E-1 convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-23 · Conversion · Disposed 285,714 · Balance 0 F1: Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: Not applicable.
Series F convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-23 · Conversion · Disposed 1,000,000 · Balance 0 F1: Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: Not applicable.

Enliven Therapeutics, Inc.

Report date March 16, 2020 · Filed March 16, 2020

Section 16 reporting ended · disclosed 2020-03-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	293,013	Reported balance After 2020-03-16 transaction · row 1 1 source row Row 1 · 2020-03-16 · Conversion · Acquired 293,013 · Balance 293,013 F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Series Seed Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-03-16 · Conversion · Disposed 125,432 · Balance 0 F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-03-16 · Conversion · Disposed 1,433,240 · Balance 0 F2: On March 16, 2020, the Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-03-16 · Conversion · Disposed 287,037 · Balance 0 F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: On March 16, 2020, the Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Evelo Biosciences, Inc.

Report date May 11, 2018 · Filed May 21, 2018

Section 16 reporting ended · disclosed 2018-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	594,443	Reported balance After 2018-05-11 transaction · row 1 1 source row Row 1 · 2018-05-11 · Conversion · Acquired 594,443 · Balance 594,443 F1: Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Series A-3 preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-05-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-05-11 · Conversion · Disposed 416,650 · Balance 0 F1: Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: Not applicable
Series B preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-05-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-05-11 · Conversion · Disposed 1,388,889 · Balance 0 F1: Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: Not applicable
Series C preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-11 · Conversion · Disposed 619,195 · Balance 0 F1: Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: Not applicable

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: Not applicable

GreenLight Biosciences Holdings, PBC

Report date July 24, 2023 · Filed July 26, 2023

Jointly reported with ALEXANDRIA REAL ESTATE EQUITIES, INC.

Section 16 reporting ended · disclosed 2023-07-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Alexandria Venture Investments, LLC	0	Reported balance After 2023-07-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-07-24 · Other · Disposed 1,609,909 · Balance 0 F1: On July 24, 2023, SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent") completed the merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, Alexandria Venture Investments, LLC ("AVI") contributed all of the shares of Common Stock held by AVI (the "Rollover Shares") to Parent in exchange for equity interests of Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2: These shares are held directly by Alexandria Venture Investments, LLC, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: On July 24, 2023, SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent") completed the merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, Alexandria Venture Investments, LLC ("AVI") contributed all of the shares of Common Stock held by AVI (the "Rollover Shares") to Parent in exchange for equity interests of Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares.

F2: These shares are held directly by Alexandria Venture Investments, LLC, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.

IDEAYA Biosciences, Inc.

Report date May 28, 2019 · Filed May 30, 2019

Section 16 reporting ended · disclosed 2019-05-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	432,384	Ending reported balance After 2019-05-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-05-28 · Conversion · Acquired 382,384 · Balance 382,384 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date. Row 2 · 2019-05-28 · Purchase · Acquired 50,000 · Balance 432,384
Series A preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-05-28 · Conversion · Disposed 3,149,405 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-05-28 · Conversion · Disposed 772,499 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Karuna Therapeutics, Inc.

Report date July 02, 2019 · Filed July 05, 2019

Section 16 reporting ended · disclosed 2019-07-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	244,447	Ending reported balance After 2019-07-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-02 · Conversion · Acquired 214,447 · Balance 214,447 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1.2987 shares of common stock upon closing of the Issuer's initial public offering on June 28, 2019, for no additional consideration. The shares had no expiration date. Row 2 · 2019-07-02 · Purchase · Acquired 30,000 · Balance 244,447
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-02 · Conversion · Disposed 165,125 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1.2987 shares of common stock upon closing of the Issuer's initial public offering on June 28, 2019, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1.2987 shares of common stock upon closing of the Issuer's initial public offering on June 28, 2019, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Korro Bio, Inc.

Report date October 07, 2019 · Filed October 09, 2019

Section 16 reporting ended · disclosed 2019-10-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	956,175	Reported balance After 2019-10-07 transaction · row 1 1 source row Row 1 · 2019-10-07 · Conversion · Acquired 956,175 · Balance 956,175 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-10-07 · Conversion · Disposed 4,161,974 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-10-07 · Conversion · Disposed 2,278,345 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Kymera Therapeutics, Inc.

Report date August 25, 2020 · Filed August 25, 2020

Section 16 reporting ended · disclosed 2020-08-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	467,932	Reported balance After 2020-08-25 transaction · row 1 1 source row Row 1 · 2020-08-25 · Conversion · Acquired 467,932 · Balance 467,932 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.
Series A convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-08-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-08-25 · Conversion · Disposed 500,000 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-08-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-08-25 · Conversion · Disposed 246,305 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Liquidia Technologies Inc

Report date July 30, 2018 · Filed August 01, 2018

Section 16 reporting ended · disclosed 2018-08-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	396,172	Ending reported balance After 2018-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-07-30 · Conversion · Acquired 259,808 · Balance 259,808 F1: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering. Row 2 · 2018-07-30 · Purchase · Acquired 136,364 · Balance 396,172
Series D preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-30 · Conversion · Disposed 4,371,889 · Balance 0 F1: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering. F2: Not applicable.
Warrant to purchase Series D preferred stockSEC Table II · derivative / convertible security · Expires 2026-12-31	Direct	0	Reported balance After 2018-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-30 · Other · Disposed 470,254 · Balance 0 F1: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering. F3: Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants.
Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2026-12-31	Direct	27,945	Reported balance After 2018-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-30 · Other · Acquired 27,945 · Balance 27,945 F3: Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants.

Filing footnotes · ownership attribution and instrument terms

F1: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering.

F2: Not applicable.

F3: Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants.

Metacrine, Inc.

Report date September 18, 2020 · Filed September 18, 2020

Section 16 reporting ended · disclosed 2020-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	1,307,256	Ending reported balance After 2020-09-18 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-09-18 · Conversion · Acquired 1,268,795 · Balance 1,268,795 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. Row 2 · 2020-09-18 · Purchase · Acquired 38,461 · Balance 1,307,256
Series A convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-09-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-09-18 · Conversion · Disposed 4,599,997 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-09-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-18 · Conversion · Disposed 1,107,899 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series C convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-09-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-18 · Conversion · Disposed 762,961 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

NextCure, Inc.

Report date May 13, 2019 · Filed May 13, 2019

Section 16 reporting ended · disclosed 2019-05-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	197,993	Reported balance After 2019-05-13 transaction · row 1 1 source row Row 1 · 2019-05-13 · Conversion · Acquired 197,993 · Balance 197,993 F1: Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-05-13 · Conversion · Disposed 223,500 · Balance 0 F1: Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date. F2: Not applicable
Series A-2 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-05-13 · Conversion · Disposed 372,500 · Balance 0 F1: Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date. F2: Not applicable
Series A-3 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-05-13 · Conversion · Disposed 365,727 · Balance 0 F1: Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date. F2: Not applicable
Series B-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-05-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-05-13 · Conversion · Disposed 628,931 · Balance 0 F1: Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date. F2: Not applicable

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date.

F2: Not applicable

Relay Therapeutics, Inc.

Report date July 20, 2020 · Filed July 20, 2020

Section 16 reporting ended · disclosed 2020-07-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	968,365	Reported balance After 2020-07-20 transaction · row 1 1 source row Row 1 · 2020-07-20 · Conversion · Acquired 968,365 · Balance 968,365 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-07-20 · Conversion · Disposed 500,000 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-20 · Conversion · Disposed 1,287,128 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-20 · Conversion · Disposed 1,651,471 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Singular Genomics Systems, Inc.

Report date June 01, 2021 · Filed June 01, 2021

Section 16 reporting ended · disclosed 2021-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	2,645,985	Reported balance After 2021-06-01 transaction · row 1 1 source row Row 1 · 2021-06-01 · Conversion · Acquired 2,645,985 · Balance 2,645,985
Series A convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-01 · Conversion · Disposed 1,796,684 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. F2: Not applicable.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-01 · Conversion · Disposed 849,301 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Vigil Neuroscience, Inc.

Report date January 11, 2022 · Filed January 11, 2022

Section 16 reporting ended · disclosed 2022-01-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	192,973	Reported balance After 2022-01-11 transaction · row 1 1 source row Row 1 · 2022-01-11 · Conversion · Acquired 192,973 · Balance 192,973 F1: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.
Series A convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-01-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-01-11 · Conversion · Disposed 392,618 · Balance 0 F1: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-01-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-01-11 · Conversion · Disposed 142,539 · Balance 0 F1: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.

Vor Biopharma Inc.

Report date February 09, 2021 · Filed February 10, 2021

Section 16 reporting ended · disclosed 2021-02-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	282,804	Reported balance After 2021-02-09 transaction · row 1 1 source row Row 1 · 2021-02-09 · Conversion · Acquired 282,804 · Balance 282,804 F1: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-02-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-09 · Conversion · Disposed 3,846,152 · Balance 0 F1: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date.

F2: Not applicable.

X4 Pharmaceuticals, Inc

Report date November 15, 2017 · Filed November 20, 2017

Section 16 reporting ended · disclosed 2017-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	225,680	Reported balance After 2017-11-15 transaction · row 1 1 source row Row 1 · 2017-11-15 · Conversion · Acquired 225,680 · Balance 225,680 F1: Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock
Series D convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-11-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-11-15 · Conversion · Disposed 770,249 · Balance 0 F1: Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock F2: Not applicable

Filing footnotes · ownership attribution and instrument terms

F1: Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock

F2: Not applicable

Xilio Therapeutics, Inc.

Report date October 26, 2021 · Filed October 26, 2021

Section 16 reporting ended · disclosed 2021-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	166,423	Reported balance After 2021-10-26 transaction · row 1 1 source row Row 1 · 2021-10-26 · Conversion · Acquired 166,423 · Balance 166,423 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-26 · Conversion · Disposed 1,581,026 · Balance 0 F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.

F2: Not applicable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2024 Filed Jun 6, 2024 22:45 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	SaleCommon Stock	150,000	$4.24	$636,000.00	Disclosure SEC source: 0001035443-24-000171 · wk-form4_1717713946.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 5,855,077 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.10 to $4.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 04, 2024 Filed Jun 6, 2024 22:45 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	SaleCommon Stock	150,000	$4.21	$631,500.00	Disclosure SEC source: 0001035443-24-000171 · wk-form4_1717713946.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 6,005,077 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.12 to $4.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
November 29, 2023 Filed Dec 1, 2023 23:53 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	575,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-23-000327 · wk-form4_1701474795.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 203,977 F1 · kind: These shares have been transferred from Alexandria Equities No. 7, LLC, ("AE7") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC, ("AE7") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F3 · ownership.nature: These securities are held directly by AE7, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
November 29, 2023 Filed Dec 1, 2023 23:53 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	575,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-23-000327 · wk-form4_1701474795.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 6,155,077 F1 · kind: These shares have been transferred from Alexandria Equities No. 7, LLC, ("AE7") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC, ("AE7") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F2 · ownership.nature: These securities are held directly by AVI, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
November 03, 2023 Filed Nov 6, 2023 21:56 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	SaleCommon Stock	143,450	$2.31	$331,369.50	Disclosure SEC source: 0001035443-23-000315 · wk-form4_1699307758.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 5,580,077 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.25 to $2.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
November 02, 2023 Filed Nov 6, 2023 21:56 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	SaleCommon Stock	103,808	$2.32	$240,834.56	Disclosure SEC source: 0001035443-23-000315 · wk-form4_1699307758.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 5,723,527 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.30 to $2.39. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
November 01, 2023 Filed Nov 2, 2023 20:44 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	SaleCommon Stock	172,742	$2.36	$407,671.12	Disclosure SEC source: 0001035443-23-000308 · wk-form4_1698957861.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 5,827,335 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.32 to $2.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
October 31, 2023 Filed Nov 2, 2023 20:44 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	SaleCommon Stock	155,000	$2.41	$373,550.00	Disclosure SEC source: 0001035443-23-000308 · wk-form4_1698957861.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 6,000,077 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.40 to $2.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
October 12, 2023 Filed Oct 16, 2023 23:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherPre-Funded Warrant · Derivative	615,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001035443-23-000283 · wk-form4_1697498217.xml · derivative · entry 4 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires not disclosed F4 · shares: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F4 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F4 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
October 12, 2023 Filed Oct 16, 2023 23:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherPre-Funded Warrant · Derivative	615,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001035443-23-000283 · wk-form4_1697498217.xml · derivative · entry 3 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subidiary Disclosed balance after: 1,500,000 Underlying: Common Stock · 615,000 shares Expires not disclosed F4 · shares: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F4 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F4 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
October 12, 2023 Filed Oct 16, 2023 23:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	1,600,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-23-000283 · wk-form4_1697498217.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 778,977 F1 · shares: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F3 · ownership.nature: These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
October 12, 2023 Filed Oct 16, 2023 23:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	1,600,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-23-000283 · wk-form4_1697498217.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By subsidiary Disclosed balance after: 6,155,077 F1 · shares: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F2 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
July 24, 2023 Filed Jul 26, 2023 20:30 UTC	GreenLight Biosciences Holdings, PBC GRNA · Entity 111075	OtherCommon Stock	1,609,909	$0.00	$0.00	Disclosure SEC source: 0001209191-23-043416 · doc4.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · See Remarks Alexandria Venture Investments, LLC · CIK 0001722024 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Alexandria Venture Investments, LLC Disclosed balance after: 0 F1 · kind: On July 24, 2023, SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent") completed the merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, Alexandria Venture Investments, LLC ("AVI") contributed all of the shares of Common Stock held by AVI (the "Rollover Shares") to Parent in exchange for equity interests of Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · price: On July 24, 2023, SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent") completed the merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, Alexandria Venture Investments, LLC ("AVI") contributed all of the shares of Common Stock held by AVI (the "Rollover Shares") to Parent in exchange for equity interests of Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2 · ownership.nature: These shares are held directly by Alexandria Venture Investments, LLC, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:37 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchaseCommon Stock Warrant · Derivative	2,950,000	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0001035443-22-000176 · wf-form4_165653503462000.xml · derivative · entry 6 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 2,950,000 Underlying: Common Stock · 2,950,000 shares Expires not disclosed F1 · price: These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant). F5 · derivative.exercise_date: The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F5 · derivative.expiration_date: The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:37 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchaseCommon Stock Warrant · Derivative	2,050,000	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0001035443-22-000176 · wf-form4_165653503462000.xml · derivative · entry 5 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 2,050,000 Underlying: Common Stock · 2,050,000 shares Expires not disclosed F1 · price: These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant). F5 · derivative.exercise_date: The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F5 · derivative.expiration_date: The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:37 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchasePre-Funded Warrant · Derivative	885,000	$1.00 Strike: $0.00	$884,911.50	Disclosure SEC source: 0001035443-22-000176 · wf-form4_165653503462000.xml · derivative · entry 4 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subidiary Disclosed balance after: 885,000 Underlying: Common Stock · 885,000 shares Expires not disclosed F1 · price: These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant). F4 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F4 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:37 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchasePre-Funded Warrant · Derivative	615,000	$1.00 Strike: $0.00	$614,938.50	Disclosure SEC source: 0001035443-22-000176 · wf-form4_165653503462000.xml · derivative · entry 3 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 615,000 Underlying: Common Stock · 615,000 shares Expires not disclosed F1 · price: These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant). F4 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F4 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:37 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchaseCommon Stock	2,065,000	$1.00	$2,065,000.00	Disclosure SEC source: 0001035443-22-000176 · wf-form4_165653503462000.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 4,555,077 F1 · price: These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant). F3 · ownership.nature: These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:37 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchaseCommon Stock	1,435,000	$1.00	$1,435,000.00	Disclosure SEC source: 0001035443-22-000176 · wf-form4_165653503462000.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 2,378,977 F1 · price: These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant). F2 · ownership.nature: These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
February 23, 2022 Filed Feb 25, 2022 21:52 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	300,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-22-000066 · wf-form4_164582594767959.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 943,977 F1 · kind: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · shares: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F3 · ownership.nature: These shares are held directly by AE7. Read SEC document
February 23, 2022 Filed Feb 25, 2022 21:52 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	300,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-22-000066 · wf-form4_164582594767959.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 2,490,077 F1 · kind: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · shares: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · price: These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F2 · ownership.nature: These shares are held directly by AVI. Read SEC document
January 11, 2022 Filed Jan 11, 2022 17:53 UTC	Vigil Neuroscience, Inc. VIGL · Entity 11675	ConversionSeries B convertible preferred stock · Derivative	142,539	$0.00	$0.00	Disclosure SEC source: 0001722024-22-000004 · wf-form4_164194159038331.xml · derivative · entry 3 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 51,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. Read SEC document
January 11, 2022 Filed Jan 11, 2022 17:53 UTC	Vigil Neuroscience, Inc. VIGL · Entity 11675	ConversionSeries A convertible preferred stock · Derivative	392,618	$0.00	$0.00	Disclosure SEC source: 0001722024-22-000004 · wf-form4_164194159038331.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 141,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. Read SEC document
January 11, 2022 Filed Jan 11, 2022 17:53 UTC	Vigil Neuroscience, Inc. VIGL · Entity 11675	ConversionCommon stock	192,973	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-22-000004 · wf-form4_164194159038331.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. Read SEC document
October 26, 2021 Filed Oct 26, 2021 16:51 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	ConversionSeries B convertible preferred stock · Derivative	1,581,026	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-21-000012 · wf-form4_163528147482023.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 166,423 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date. Read SEC document
October 26, 2021 Filed Oct 26, 2021 16:51 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	ConversionCommon stock	166,423	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-21-000012 · wf-form4_163528147482023.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date. Read SEC document
June 01, 2021 Filed Jun 1, 2021 17:22 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	ConversionSeries B convertible preferred stock · Derivative	849,301	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-21-000008 · wf-form4_162258255031726.xml · derivative · entry 3 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 849,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. Read SEC document
June 01, 2021 Filed Jun 1, 2021 17:22 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	ConversionSeries A convertible preferred stock · Derivative	1,796,684	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-21-000008 · wf-form4_162258255031726.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,796,684 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date. Read SEC document
June 01, 2021 Filed Jun 1, 2021 17:22 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	ConversionCommon stock	2,645,985	$0.00	$0.00	Disclosure SEC source: 0001722024-21-000008 · wf-form4_162258255031726.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 17, 2021 Filed Feb 19, 2021 22:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	43,478	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-21-000049 · wf-form4_161377301066645.xml · nonDerivative · entry 3 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 2,190,077 F2 · shares: These shares have been transferred from AE7 to Alexandria Venture Investments, LLC ("AVI") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F2 · price: These shares have been transferred from AE7 to Alexandria Venture Investments, LLC ("AVI") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F3 · ownership.nature: These shares are held directly by AVI. Read SEC document
February 17, 2021 Filed Feb 19, 2021 22:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	OtherCommon Stock	43,478	Not disclosed	Not disclosed	Disclosure SEC source: 0001035443-21-000049 · wf-form4_161377301066645.xml · nonDerivative · entry 2 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 1,243,977 F2 · shares: These shares have been transferred from AE7 to Alexandria Venture Investments, LLC ("AVI") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F2 · price: These shares have been transferred from AE7 to Alexandria Venture Investments, LLC ("AVI") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc. F1 · ownership.nature: These shares are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
February 17, 2021 Filed Feb 19, 2021 22:17 UTC	Applied Therapeutics, Inc. APLT · Entity 67708	PurchaseCommon Stock	43,478	$23.00	$999,994.00	Disclosure SEC source: 0001035443-21-000049 · wf-form4_161377301066645.xml · nonDerivative · entry 1 ALEXANDRIA REAL ESTATE EQUITIES, INC. · CIK 0001035443 · 10% owner Alexandria Equities No. 7, LLC · CIK 0001776437 · 10% owner Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 1,287,455 F1 · ownership.nature: These shares are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. Read SEC document
February 09, 2021 Filed Feb 10, 2021 00:40 UTC	Vor Biopharma Inc. VOR · Entity 4763	ConversionSeries B convertible preferred stock · Derivative	3,846,152	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-21-000004 · wf-form4_161291759833114.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 282,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date. Read SEC document
February 09, 2021 Filed Feb 10, 2021 00:40 UTC	Vor Biopharma Inc. VOR · Entity 4763	ConversionCommon stock	282,804	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-21-000004 · wf-form4_161291759833114.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date. Read SEC document
December 08, 2020 Filed Dec 8, 2020 21:36 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	ConversionSeries B redeemable convertible preferred stock · Derivative	1,168,347	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000020 · wf-form4_160746339873406.xml · derivative · entry 3 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 314,664 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
December 08, 2020 Filed Dec 8, 2020 21:36 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	ConversionSeries A redeemable convertible preferred stock · Derivative	1,428,570	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000020 · wf-form4_160746339873406.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 384,748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
December 08, 2020 Filed Dec 8, 2020 21:36 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	ConversionCommon stock	699,412	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000020 · wf-form4_160746339873406.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
September 18, 2020 Filed Sep 18, 2020 19:10 UTC	Metacrine, Inc. MTCR · Entity 115177	ConversionSeries C convertible preferred stock · Derivative	762,961	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000016 · wf-form4_160047059351258.xml · derivative · entry 5 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 149,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
September 18, 2020 Filed Sep 18, 2020 19:10 UTC	Metacrine, Inc. MTCR · Entity 115177	ConversionSeries B convertible preferred stock · Derivative	1,107,899	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000016 · wf-form4_160047059351258.xml · derivative · entry 4 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 217,235 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
September 18, 2020 Filed Sep 18, 2020 19:10 UTC	Metacrine, Inc. MTCR · Entity 115177	ConversionSeries A convertible preferred stock · Derivative	4,599,997	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000016 · wf-form4_160047059351258.xml · derivative · entry 3 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 901,960 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
September 18, 2020 Filed Sep 18, 2020 19:10 UTC	Metacrine, Inc. MTCR · Entity 115177	PurchaseCommon stock	38,461	$13.00	$499,993.00	Disclosure SEC source: 0001722024-20-000016 · wf-form4_160047059351258.xml · nonDerivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307,256 Read SEC document
September 18, 2020 Filed Sep 18, 2020 19:10 UTC	Metacrine, Inc. MTCR · Entity 115177	ConversionCommon stock	1,268,795	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000016 · wf-form4_160047059351258.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,268,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
August 25, 2020 Filed Aug 25, 2020 22:36 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	ConversionSeries B convertible preferred stock · Derivative	246,305	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000012 · wf-form4_159839496225044.xml · derivative · entry 3 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 154,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
August 25, 2020 Filed Aug 25, 2020 22:36 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	ConversionSeries A convertible preferred stock · Derivative	500,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000012 · wf-form4_159839496225044.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 313,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
August 25, 2020 Filed Aug 25, 2020 22:36 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	ConversionCommon Stock	467,932	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000012 · wf-form4_159839496225044.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
July 20, 2020 Filed Jul 20, 2020 22:12 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	ConversionSeries C Preferred Stock · Derivative	1,651,471	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000009 · wf-form4_159528299083836.xml · derivative · entry 4 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 465,082 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2 · derivative.expiration_date: Not applicable. Read SEC document
July 20, 2020 Filed Jul 20, 2020 22:12 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	ConversionSeries B Preferred Stock · Derivative	1,287,128	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000009 · wf-form4_159528299083836.xml · derivative · entry 3 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 362,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2 · derivative.expiration_date: Not applicable. Read SEC document
July 20, 2020 Filed Jul 20, 2020 22:12 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	ConversionSeries A Preferred Stock · Derivative	500,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000009 · wf-form4_159528299083836.xml · derivative · entry 2 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. F2 · derivative.expiration_date: Not applicable. Read SEC document
July 20, 2020 Filed Jul 20, 2020 22:12 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	ConversionCommon Stock	968,365	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000009 · wf-form4_159528299083836.xml · nonDerivative · entry 1 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date. Read SEC document
June 16, 2020 Filed Jun 16, 2020 20:38 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	ConversionSeries C convertible preferred stock · Derivative	134,126	Not disclosed	Not disclosed	Disclosure SEC source: 0001722024-20-000005 · wf-form4_159233990259960.xml · derivative · entry 4 Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 63,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date. F2 · price: Not applicable. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date. F2 · derivative.expiration_date: Not applicable. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.